It has been shown that BTK negatively regulates maturation of DCs and BTK−/− DCs exhibit more mature phenotypes and stronger T cell-stimulatory ability.15 A recent study from our group identified that ibrutinib-treatment-induced DC activation and maturation by upregulating CD80, MHC-II, and C-C chemokine receptor type 7.16 In line with these findings, our present study revealed that ibrutinib treatment significantly increased mature DCs in the spleens as well as tumours while the immature DC proportion remained elevated in the vehicle group. The gene discussed is BTK; the disease is neoplasm.